NEOATRICON Solution for infusion Ref.[114544] Active ingredients: Dopamine

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: BrePco Biopharma Ltd., Suite One, The Avenue, Beacon Court, Sandyford, Dublin D18HX31, Ireland

Product name and form

Neoatricon 1.5 mg/mL solution for infusion.

Neoatricon 4.5 mg/mL solution for infusion.

Pharmaceutical Form

Solution for infusion.

The solution is clear and colourless to pale yellow with a pH of 2.5 to 5.5.

Neoatricon 1.5 mg/ mL solution for infusion: Osmolarity is 20 mOsmol/kg.

Neoatricon 4.5 mg/ mL solution for infusion: Osmolarity is 50 mOsmol/kg.

Qualitative and quantitative composition

Neoatricon 1.5 mg/mL solution for infusion

Each mL of solution contains 1.5 mg of dopamine hydrochloride.

Each vial contains 45 mg of dopamine hydrochloride in 30 mL.

Excipient with known effect: Each vial contains 9 mg sodium metabisulfite.

Neoatricon 4.5 mg/mL solution for infusion

Each mL of solution contains 4.5 mg of dopamine hydrochloride.

Each vial contains 225 mg of dopamine hydrochloride in 50 mL.

Excipient with known effect: Each vial contains 15 mg of sodium metabisulfite.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Dopamine

Dopamine hydrochloride stimulates adrenergic receptors of the sympathetic nervous system. Dopamine hydrochloride has principally a direct stimulatory effect on β1-adrenergic receptors, but also appears to have an indirect effect by releasing norepinephrine from its storage sites. Dopamine hydrochloride also appears to act on specific dopaminergic receptors in the renal, mesenteric, coronary, and intracerebral vascular beds to cause vasodilation.

List of Excipients

Sodium metabisulfite (E223)
Dilute hydrochloric acid (for pH-adjustment)
Sodium hydroxide (for pH-adjustment)
Water for injections

Pack sizes and marketing

Type I clear glass vial with bromobutyl rubber stopper, sealed with flip-off aluminium seal.

Pack size:

Neoatricon 1.5 mg/mL solution for infusion: single carton containing 30 mL vial.

Neoatricon 4.5 mg/mL solution for infusion: single carton containing 50 mL vial.

Not all pack sizes may be marketed.

Marketing authorization holder

BrePco Biopharma Ltd., Suite One, The Avenue, Beacon Court, Sandyford, Dublin D18HX31, Ireland

Marketing authorization dates and numbers

EU/1/24/1804/001 – 1.5 mg / ml 1 vial
EU/1/24/1804/002 – 4.5 mg / ml 1 vial

Drugs

Drug Countries
NEOATRICON Lithuania

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.